Company Overview

MAKScientific, LLC, a privately held Boston-based company founded in 2004 on the basis of research by a distinguished

scientist in the chemistry and biochemistry of cannabinoids. The Company is a leader in endocannabinoid research

with the ability to address major unmet medical needs for selected diseases with a clear competitive advantage over

present therapies. Our mission is the discovery, development and commercialization of novel therapeutics in the areas

of neuropathic and inflammatory pain, obesity, metabolic disorders, neuroprotection and addiction.

MAKScientific holds a proprietary understanding and extensive expertise in the endocannainoid biochemical pathways

and has validated therapeutic targets.  These include two known GPCRs (CB1 and CB2) as well as enzymes that are

involved in the modulation of this biochemical system including fatty acid amide hydrolase (FAAH) and monoacylglyceral

lipase (MGL) as well as the cannabinoid transporter system. The Company has proficiency in medicinal chemistry and

drug design and has substantial drug development assets that include a large library of carefully designed druggable

cannabinergic compounds as well as advanced preclinical candidates in fatty liver disease, neuropathies produced by

cancer chemotherapy, multiple sclerosis and nicotine addiction. 

Founder's Accomplishments

Professor Makriyannis is among the first to define the biochemical pathways of endocannabinoids through the development of highly selective ligands for endocannabinoid targets.  Some of the highlights are:

• 1994 Early cannabinoid receptor antagonists (AM251)
• 1995 First CB2 receptor antagonist (AM630)
• 1966 First to develop ametabotically stable endocannabinoid (AM356)
• 1966 First fatty acid amide hydrolase (FAAH) inhibitors (AM374) as medications for pain and neurodegenerative diseases
  

• 1997 First discovery of anandamide transporter (AM404)
  
• 1997 First anadmide reuptake inhibitor (AM404)
  
• 1998 First in vivo imaging agent for the CB1 receptor (AM281)
  
• 1999 First highly selective CB2 agonists (AM1710, AM1241)
• 2001 First CB2 candidates for neuropathic pain (MAK1400)
  
• 2004 First CB1 neutral antagonists (AM4113, AM6527)
• 2005 Developed early potent and selective FAAH inhibitors (AM3506)
• 2009 Early selective inhibitors for MGL (MAK2028)
  
• 2010 First CB1 peripherally acting neutral antagonist with reduced side effects (AM6545)
  

To find out more about Dr. Makriyannis' professional activities please use link below:

http://www.cdd.neu.edu